Flag of the European Union EU Clinical Trials Register Help

Clinical trials for exenatide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    87 result(s) found for: exenatide. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2006-006149-15 Sponsor Protocol Number: H80-MC-GWBO Start Date*: 2007-06-21
    Sponsor Name:Eli Lilly and Company
    Full Title: The effect of treatment interruption on safety and efficacy of exenatide in patients with Type 2 Diabetes.
    Medical condition: Type 2 Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001437-12 Sponsor Protocol Number: Ex17 Start Date*: 2017-06-12
    Sponsor Name:University of Tartu
    Full Title: Effect of exenatide on cortisol secretion
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000238-23 Sponsor Protocol Number: ExeBAT01 Start Date*: 2016-08-09
    Sponsor Name:Leiden University Medical Center
    Full Title: The effect of Exenatide on brown adipose tissue activity and energy expenditure in healthy young men
    Medical condition: Healthy volunteers, intended indications: obesity and dyslipidemia
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000790-21 Sponsor Protocol Number: ESR-15-10862 Start Date*: 2017-01-04
    Sponsor Name:Radboudumc
    Full Title: Effect of the GLP-1 receptor agonist exenatide on impaired hypoglycaemic awareness in type 1 diabetes
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000732-26 Sponsor Protocol Number: ExPD-ESR-18-13512 Start Date*: 2019-10-23
    Sponsor Name:Stockholm Health Care Services
    Full Title: Effect of Exenatide on disease progression in early Parkinson's disease.
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004709-42 Sponsor Protocol Number: NL63792.099.17 Start Date*: 2018-04-24
    Sponsor Name:Martini Hospital
    Full Title: An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002780-16 Sponsor Protocol Number: 8.4 Start Date*: 2012-06-11
    Sponsor Name:Karolinska Institutet
    Full Title: PROLOGUES - Prehospital lowering of glucose in Stroke
    Medical condition: Patients with hyperglycemia and symptoms of acute stroke will be randomized to either subcutaneous injection with 10ug of Byetta or standard care.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002691-33 Sponsor Protocol Number: H8O-MC-GWCD Start Date*: 2007-07-11
    Sponsor Name:Eli Lilly and Company Ltd
    Full Title: A Study to Assess the Effect of Exenatide Treatment on Mean 24-hour Heart Rate in Patients with Type 2 Diabetes
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005534-36 Sponsor Protocol Number: Scope Start Date*: 2008-02-04
    Sponsor Name:King's College Hospital [...]
    1. King's College Hospital
    2. King's College London
    Full Title: The effect of Exenatide on satiety, metabolic parameters and regional brain activation in response to nutrient ingestion in Type 2 diabetes.
    Medical condition: The brainﾒs response to food ingestion can be imaged and preliminary data suggest that these responses are different in the obese and insulin resistant. We will investigate the hypothesis that Exen...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022792-57 Sponsor Protocol Number: 2010-14 Start Date*: 2011-01-11
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
    Full Title: Effet d’un agoniste du récepteur au GLP1 (Exenatide) sur le contenu en triglycérides intramyocardique chez le patient obèse diabétique.
    Medical condition: patient obèse diabétique
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005196-16 Sponsor Protocol Number: H8O-MC-GWBQ Start Date*: 2012-07-24
    Sponsor Name:Amylin Pharmaceuticals, Inc.
    Full Title: Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes
    Medical condition: Treatment of Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-000577-65 Sponsor Protocol Number: 2993-114 Start Date*: 2004-08-30
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, randomized, open label, comparator-controlled, parallel-group, multicentre study to compare the effects of exenatide and insulin glargine on beta cell function and cardiovascular risk ma...
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-000573-54 Sponsor Protocol Number: H80-MC-GWAN Start Date*: 2006-09-29
    Sponsor Name:Eli Lilly and Company
    Full Title: An open label study examining the long term safety of exenatide given twice daily to patients with type 2 diabetes mellitus.
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003432-39 Sponsor Protocol Number: D1690L00016 Start Date*: 2014-11-19
    Sponsor Name:Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University
    Full Title: A 24-week, single centre, randomized, parallel-group, double-blind, placebo controlled Phase II study to evaluate the efficacy on body weight of dapagliflozin 10 mg once daily in combination with e...
    Medical condition: Obesity defined as body mass index (BMI) 30-45 kg/m2 Obesity related metabolic disorders
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003738-25 Sponsor Protocol Number: ESR-16-12160/UKE-DapEx-001 Start Date*: 2017-12-28
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared...
    Medical condition: Obese insulin-resistant patients with Type 2 Diabetes mellitus (T2DM) and inadequate glycemic control (HbA1c ≥ 8.0% and ≤ 11.0%)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003363-64 Sponsor Protocol Number: 13/0384 Start Date*: 2014-04-03
    Sponsor Name:University College London
    Full Title: A randomised, double blind, placebo controlled, single centre, 60 week trial of Exenatide once weekly for the treatment of moderate severity Parkinson’s disease.
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006928-55 Sponsor Protocol Number: PCOS-NASH-2009 Start Date*: 2009-03-26
    Sponsor Name:Hull and East Yorkshire NHS Trust
    Full Title: Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Exenatide?
    Medical condition: Women with polycystic ovary syndrome and nonalcoholic steatohepatitis
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001869-29 Sponsor Protocol Number: 2515/2008 Start Date*: 2008-08-05
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Mechanism of action and metabolic effects of exenatide in obesity
    Medical condition: no diabetic, obese subjects with BMI≥40 kg.m-2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006251-46 Sponsor Protocol Number: V4ByIns Start Date*: Information not available in EudraCT
    Sponsor Name:Institute of Diabetes “Gerhardt Katsch”
    Full Title: Prediction of the efficacy of exenatide treatment in suboptimally controlled type 2 diabetic patients by “Metabolic Fingerprint” and evidence-based KADIS® decision support: a clinical pilot trial
    Medical condition: the trial will be performed in a total of 58 male and female patients with type 2 diabetes who will be assigned to two groups, receiving either exenatide or insulin glargine
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003598-41 Sponsor Protocol Number: FRDA-GLP1-2014 Start Date*: 2014-10-02
    Sponsor Name:CUB - Hôpital Erasme
    Full Title: Pilot study of incretin analogs as new therapeutics for Friedreich's Ataxia.
    Medical condition: Friedreich's Ataxia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 06:45:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA